Dr. Sandra Adams

Dr. Sandra Adams is a board-certified medical oncologist specialising in gynaecological cancers and haematological malignancies. She completed her medical education at the University of Miami Miller School of Medicine and gynaecological oncology fellowship at the Moffitt Cancer Center in Tampa, gaining expertise in the surgical and systemic management of ovarian, endometrial, cervical, and vulvar cancers. She subsequently undertook additional fellowship training in haematological oncology, broadening her scope to include lymphoma and leukaemia management.

Dr. Adams is a recognised expert in the treatment of ovarian cancer, from initial cytoreductive surgery through platinum-based chemotherapy, PARP inhibitor maintenance, and management of relapsed disease with bevacizumab and emerging agents. She participates in a weekly gynaecological oncology tumour board and co-leads an ovarian cancer surveillance programme for women with BRCA1 and BRCA2 pathogenic variants, providing genetic counselling, risk-reduction surgery discussions, and enhanced screening.

Her haematological oncology practice encompasses the management of lymphomas and acute leukaemias, with particular expertise in elderly patients for whom treatment intensity must be carefully balanced against comorbidity burden. She has published studies on treatment tolerance and outcomes in older patients with diffuse large B-cell lymphoma and on the management of treatment-related haematological toxicities during gynaecological cancer treatment.

Dr. Adams is deeply sensitive to the specific challenges faced by women with gynaecological cancers, including fertility preservation considerations in younger patients, sexual health impacts of treatment, and the psychological dimension of cancer affecting reproductive organs. She works closely with psycho-oncology, sexual health, and fertility preservation teams to address these dimensions proactively, and has received the Moffitt Cancer Center's Excellence in Patient-Centred Care Award.